| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Total revenue | 0 | |||
| General and administrative | 1,443,827 | |||
| Research and development | 2,729,891 | |||
| Collaboration credits | 1,658,248 | |||
| In-process r&d impairment | 0 | |||
| Change in fair value of contingent consideration | -1,721,033 | |||
| Total operating expenses | 794,437 | |||
| Operating (loss) income | -794,437 | |||
| Interest income, net | 201,822 | |||
| Other expense, net | -23,708 | |||
| Total other income, net | 178,114 | |||
| (loss) income before income tax benefit | -616,323 | |||
| Income tax benefit | -643,129 | |||
| Net (loss) income | 26,806 | |||
| Net Income Loss From Continuing Operations Available To Common Shareholders Basic | 26,806 | |||
| Net (loss) income attributable to common shareholders | 26,806 | |||
| Net (loss) income per common share - basic (in usd per share) | 0.01 | |||
| Net (loss) income per common share - diluted (in usd per share) | 0.01 | |||
| Weighted average shares outstanding - basic (in shares) | 4,289,853 | |||
| Weighted average shares outstanding - diluted (in shares) | 4,361,740 | |||
KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC (KPRX)